Copenhagen, Denmark – Demant A/S, a global leader in hearing healthcare, has announced a significant restructuring program, including the reduction of approximately 700 positions worldwide, following a turbulent financial year marked by softer industry growth and compressed profit margins. The comprehensive initiative aims to reset the company’s cost base and enhance long-term profitability, with an anticipated annual cost saving of DKK 500 million (approximately US$79 million) by 2028. Crucially for the North American market, Demant has affirmed that these organizational changes are primarily targeted at administrative functions outside the United States and will not impact professional services or customer-facing roles within the U.S. hearing care provider network.
The announcement came alongside the release of Demant’s Annual Report 2025, which detailed the company’s full-year financial performance and outlined a strategic profitability drive. Demant, the parent company of renowned brands such as Oticon, Bernafon, and numerous leading diagnostic and special equipment manufacturers, operates at the forefront of innovation and service in the hearing industry. Despite achieving its twice-revised sales forecasts for 2025, the company faced considerable headwinds that ultimately necessitated a decisive move towards operational efficiency.
2025 Financial Performance: A Mixed Picture
For the 2025 financial year, Demant reported a revenue growth of 5%, with 2% stemming from organic growth, reaching an EBIT (Earnings Before Interest and Taxes) of DKK 3.960 billion (approximately US$626 million) before special items. This translated into an operating margin of 17.2%. While these figures reflect a degree of resilience in a challenging market, the underlying narrative presented a "good news-bad news" scenario for the Danish conglomerate.
The "good news" highlighted Demant’s ability to meet its adjusted organic sales forecasts for 2025, a testament to its market position and product portfolio, even as the broader industry struggled with flat or even slightly negative growth in key markets, particularly the United States. However, the "bad news" revealed a significant dip in profitability, with EBIT decreasing by approximately 7% compared to the previous year. This erosion of profit margins, despite sales growth, underscored the intense competitive pressures and rising operational costs that have characterized the global hearing healthcare sector in recent times. The discrepancy between sales performance and profitability served as the primary catalyst for the new, aggressive cost-saving program.
Navigating Macroeconomic Headwinds and Consumer Hesitation
Demant’s 2025 year-end financial report echoed sentiments broadly expressed across the global hearing aid manufacturing industry: pervasive macroeconomic uncertainties have significantly impacted consumer behavior. These uncertainties, including persistent inflation, rising interest rates, and a general climate of economic caution, have led to a "reduced willingness to invest" among consumers, resulting in "delayed purchases" of discretionary items such as hearing aids. This trend has not only stifled overall market growth but has also intensified competition as manufacturers vie for a shrinking pool of immediate buyers.
Søren Nielsen, Demant’s CEO, articulated this challenge during a recent conversation at the U.S. launch of the Oticon Zeal product. Nielsen observed that even in Denmark, a market where roughly half the population benefits from free hearing aids, the market remains stagnant due to prevailing economic anxieties. "You don’t take the step [toward getting a hearing aid] if you’re not comfortable about how the world is going to develop," Nielsen explained. He elaborated that this global phenomenon of uncertainty is causing individuals to "hold back… so they’re just postponing purchases a little bit." This postponement, even if temporary, accumulates to a significant drag on market expansion and profitability for manufacturers. The discretionary nature of hearing aid purchases, often considered an investment in quality of life rather than an immediate necessity by consumers, makes the sector particularly vulnerable to shifts in economic confidence.
A Proactive Cost-Saving Plan for Long-Term Sustainability
In response to these market dynamics and the imperative to restore profitability, Demant has embarked on a multi-faceted, permanent, and long-term cost-saving initiative designed to structurally reshape its operations over the next two years. The company has identified several key strategic levers for achieving these efficiencies:
- Shifting Work to More Cost-Effective Locations: This involves relocating certain operational and administrative functions to regions where labor and overhead costs are lower, leveraging global talent pools more strategically.
- Prioritizing Activities: A thorough review of all company activities will be undertaken to identify and eliminate non-essential tasks or those that do not directly contribute to core business objectives and value creation.
- Increasing Efforts to Lower Production Costs: This includes optimizing manufacturing processes, investing in automation, and exploring new technologies to reduce the cost of goods sold without compromising quality.
- Tightening Procurement: Implementing more rigorous procurement strategies, negotiating better terms with suppliers, and consolidating purchasing power to achieve significant savings on raw materials, components, and services.
These structural changes are projected to affect approximately 700 employees globally by 2026. Of this total, roughly 150 positions will be reduced within Denmark, the company’s home base. The ambitious plan is expected to generate annual cost savings of around DKK 500 million (approximately US$79 million), with the full financial effect realized by 2028. Significantly, Demant anticipates achieving a substantial portion of these savings relatively quickly, with DKK 250 million (approximately US$39 million) in savings already projected for 2026. This aggressive timeline underscores the company’s commitment to swiftly improving its financial health.
){kind=logo}
Assurance for the U.S. Market: Uninterrupted Professional Services
A key aspect of Demant’s communication regarding these changes has been its explicit assurance to the U.S. market. A representative from Oticon US, with direct knowledge of the situation, confirmed to HearingTracker that the announced staff reductions would not significantly impact operations in the United States. This means that U.S. hearing care providers can expect no cuts to vital customer-facing roles. Positions such as field representatives, customer service personnel, and other related support functions that are crucial for seamless service delivery and professional engagement will remain unaffected.
The representative clarified that the job cuts are predominantly aimed at administrative positions located outside the U.S., as Demant seeks to streamline its global functions and reallocate resources more efficiently. While not explicitly mentioned by the spokesperson, this administrative streamlining could also be partially attributed to the company’s recent strategic acquisition. In 2025, Demant acquired the KIND Group, one of Germany’s largest dispensing networks, boasting approximately 650 locations. Such a significant acquisition inevitably leads to a degree of functional overlap, particularly in administrative and back-office operations, presenting a natural opportunity for consolidation and efficiency gains post-integration. The strategic decision to shield the U.S. customer-facing roles reflects Demant’s understanding of the critical importance of maintaining strong relationships and robust support for hearing care professionals in one of its largest and most competitive markets.
Outlook: Modest Market Growth and Improving Profitability on the Horizon
Looking ahead, Demant has provided a cautious but optimistic outlook for the global hearing aid market. For 2026, the company assumes a global hearing aid market value growth of 2-4%. While this forecast is described as conservative and "temporarily below" its medium- to long-term assumptions (which historically average 4-6% growth over the past decade), it signals a projected stabilization and gradual recovery after the recent turbulent period.
For its own performance in 2026, Demant is guiding towards 3-6% organic growth. Furthermore, the company projects an EBIT before special items of DKK 4,100–4,500 million (approximately US$648–711 million). A significant portion of this anticipated improvement in profitability is expected to come from the newly implemented profitability initiative, which is projected to contribute roughly DKK 250 million (approximately US$39 million) to EBIT before special items in 2026. The benefits of these cost-saving measures are expected to accrue more heavily in the second half of the year as the planned actions fully ramp up and take effect.
)
Additionally, the acquisition of the KIND Group is anticipated to make a substantial contribution to Demant’s financial performance, with an expected DKK 300 million (approximately US$47 million) to EBIT before special items in 2026. This indicates that while the KIND acquisition presented integration challenges and potential administrative overlaps, it is also poised to be a significant driver of future earnings.
Innovation Amidst Austerity: The Role of New Product Launches
Even as Demant implements stringent cost-cutting measures, the company remains committed to innovation as a cornerstone of its growth strategy. Oticon, one of Demant’s flagship brands, launched the unique Zeal NXT instant-fit in-ear hearing aid at EUHA in Germany in October of the previous year. Its subsequent debut two weeks prior in Phoenix, U.S., was met with positive reception from attending hearing care professionals. This product exemplifies Demant’s ongoing investment in advanced hearing technology, offering modern connectivity and rechargeability in a discreet form factor. Market analysts are now speculating that Oticon may follow the successful Zeal launch with a new flagship product line later this year, further solidifying its position at the forefront of technological advancement in the hearing aid industry.
The juxtaposition of aggressive cost reduction and continued product innovation highlights Demant’s dual strategy: optimizing its operational base to navigate current economic uncertainties while simultaneously investing in research and development to secure future market leadership. The aim is to emerge from this period of global economic volatility as a leaner, more efficient, and technologically advanced organization, better equipped to serve the evolving needs of the global hearing healthcare market. This strategic recalibration underscores Demant’s long-term vision for sustained growth and profitability in a dynamic and increasingly competitive industry.